← Back to All Filings

Zoetis Inc. Director Mark Stetter Acquires Phantom Stock Units via Deferred Retainer

Low SignificanceSeptember 18, 2026 at 10:14:42 PM UTC

Zoetis Inc.

$ZTS4CIK: 0001555280

Subscribe to track ZTS

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Zoetis Inc. ($ZTS) - Form 4 Filing SummaryInsider: Mark Stetter (Director) • Transaction Date: September 17, 2026 • Type: Acquisition (Award / Deferred Retainer Allocation) • Security: Phantom Stock Unit • Shares Transacted: 342.372 @ $73.02 • Total Value: ~$25,000.00 • Post-Transaction Holdings: 880.1751 units • Significance: Low (Routine non-employee director deferred retainer fee allocation)

Comprehensive Analysis

Overview & Context

On September 18, 2026, Zoetis Inc. (NYSE: ZTS) filed a Form 4 on behalf of Director Mark Stetter. The transaction occurred on September 17, 2026, involving the acquisition of 342.372 phantom stock units at a conversion/reference price of $73.02 per share, amounting to approximately $25,000.00.

Transaction Details

  • Filing Date: September 18, 2026
  • Transaction Date: September 17, 2026
  • Reporting Person: Mark Stetter (Director)
  • Nature of Acquisition: Pursuant to the Zoetis Inc. Amended and Restated Non-Employee Director Deferred Compensation Plan, the reporting person elected to defer cash retainer fees into phantom stock units tied to the Zoetis stock fund. The transaction also includes 3.7148 dividend equivalent units.
  • Settlement Terms: Each unit corresponds to one share of common stock and will settle in cash following the director's separation from service.
  • Post-Transaction Ownership: Following this transaction, Mark Stetter directly holds 880.1751 phantom stock units.

Trading Significance

The trading significance of this transaction is Low. The acquisition does not represent open-market buying or discretionary equity purchases; rather, it reflects a routine, plan-based deferral of non-employee director compensation into cash-settled phantom stock.

Topics:#Zoetis#ZTS#InsiderTrading#Form4#Pharma

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.